Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 993Neoplasms 852Carcinoma, Non-Small-Cell Lung 845Prostatic Neoplasms 528Neoplasm Metastasis 501Leukemia, Myeloid, Acute 489Melanoma 456Colorectal Neoplasms 447Multiple Myeloma 441Lung Neoplasms 422Pancreatic Neoplasms 353Recurrence 350Lymphoma 350Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 329Leukemia 324Leukemia, Lymphocytic, Chronic, B-Cell 302Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 245Carcinoma, Hepatocellular 234Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Myelodysplastic Syndromes 231Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

infigratinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Hypophosphatemia × Clear all
NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

NCT00622479 2014-12-18

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Bayer

Phase 1 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Hypophosphatemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡